Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
Association of TROP2 quantitative continuous scoring normalised membrane ratio with efficacy in Chinese patients with advanced/metastatic non-small cell lung cancer treated with datopotamab deruxtecan in TROPION-PanTumor02
Yi-Long Wu
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
Effects of datopotamab deruxtecan (Dato-DXd) vs docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic nonsquamous (NSQ) non-small cell lung cancer (NSCLC): Results from TROPION-LUNG01
Robin Cornelissen
Oral
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
Osimertinib + datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD
Xiuning Le
Poster
HER3-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
Phase 1 study of patritumab deruxtecan (HER3-DXd) in patients with advanced KRAS G12C non-small cell lung cancer: Study U102 cohort 5
Luis Paz-Ares
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
TROPION-Lung10: Phase 3 study of datopotamab deruxtecan plus rilvegostomig in non-squamous advanced or metastatic non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations
Thomas Newsom-Davis
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer
Sarah Goldberg
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Lung Cancer
TROPION-Lung15: A phase 3 study of datopotamab deruxtecan ± osimertinib vs platinum-doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer and disease progression on prior osimertinib
Ernest Nadal